Search Result

Results for "

2-Aminopyrimidine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Antibiotic (1) Apoptosis (2) Bacterial (1) Biochemical Assay Reagents (4) CDK (2) DNA/RNA Synthesis (1) Drug Intermediate (2) EGFR (1) Endothelin Receptor (1) Ephrin Receptor (1) GCGR (1) GnRH Receptor (1) Histone Demethylase (1) Insulin Receptor (1) Isotope-Labeled Compounds (1) Melanocortin Receptor (1) P-glycoprotein (1) Parasite (1) PSMA (2) Radionuclide-Drug Conjugates (RDCs) (4) Reference Standards (1) Renin (1) Somatostatin Receptor (5)
By Research Areas:	Cancer (13) Cardiovascular Disease (1) Endocrinology (2) Infection (1) Metabolic Disease (3) Neurological Disease (4)

By Targets:

Amyloid-β (1)

Antibiotic (1)

Apoptosis (2)

Bacterial (1)

Biochemical Assay Reagents (4)

CDK (2)

DNA/RNA Synthesis (1)

Drug Intermediate (2)

EGFR (1)

Endothelin Receptor (1)

Ephrin Receptor (1)

GCGR (1)

GnRH Receptor (1)

Histone Demethylase (1)

Insulin Receptor (1)

Isotope-Labeled Compounds (1)

Melanocortin Receptor (1)

P-glycoprotein (1)

Parasite (1)

PSMA (2)

Radionuclide-Drug Conjugates (RDCs) (4)

Reference Standards (1)

Renin (1)

Somatostatin Receptor (5)

By Research Areas:

Cancer (13)

Cardiovascular Disease (1)

Endocrinology (2)

Infection (1)

Metabolic Disease (3)

Neurological Disease (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P4070

Insulin icodec	Insulin Receptor	Metabolic Disease
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA_1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus ^[2].

HY-41340

*2-Aminopyrimidine*	Biochemical Assay Reagents Drug Intermediate	Others
2-Aminopyrimidine is an important heterocyclic intermediate. 2-Aminopyrimidine can undergo various reactions such as alkylation and acylation, and can be used for the synthesis of other active compounds .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor *SSTR2* with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of *SSTR2* and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors ^[2].

HY-P2336A

CCZ01048 TFA 3 Publications Verification	Melanocortin Receptor	Cancer
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-41340R

2-Aminopyrimidine (Standard)	Biochemical Assay Reagents Reference Standards Drug Intermediate	Others
2-Aminopyrimidine (Standard) is the analytical standard of 2-Aminopyrimidine (HY-41340). This product is intended for research and analytical applications. 2-Aminopyrimidine is an important heterocyclic intermediate. 2-Aminopyrimidine can undergo various reactions such as alkylation and acylation, and can be used for the synthesis of other active compounds.

HY-W720946

2-Aminopyrimidine-d2	Isotope-Labeled Compounds Biochemical Assay Reagents	Others
2-Aminopyrimidine-d₂ is the deuterium labeled 2-Aminopyrimidine (HY-41340). 2-Aminopyrimidine is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-162530

CDK4/6-IN-20	CDK	Cancer
CDK4/6-IN-20 (Compound II-5) is a CDK4/CDK6 inhibitor with IC₅₀ values of 1.9, 14.2 nM, respectively. CDK4/6-IN-20 also inhibits cell proliferation and can be used in cancer research .

HY-132994

TVD-0003510	Biochemical Assay Reagents	Others
TVD-0003510 is a carboxamide derivative, and involves in synthesis of (2-((6-(2-aminopyrimidine-5-carboxamido)-8-methoxy-3,4-dihydro-2H-pyrimido[1,2-c]quinazolin-9-yl)oxy)ethyl)piperazine-l-carboxylate (C51), as a part of tert-butyl2-(4-hydroxyphenyl)acetate .

HY-P11004

A3-APO	Bacterial Antibiotic	Infection
A3-APO is an antimicrobial peptide. A3-APO has a significant antimicrobial activity by a dual mode of action with both membrane disintegration and intracellular target inhibition. A3-APO can deactivate bacterial toxins and increase the expression of anti-inflammatory cytokines (such as IL-4 and IL-10), without antimicrobial resistance. A3-APO accelerates burn wounds healing in mice infection model of Acinetobacter baumannii and Staphylococcus aureus .

HY-P10472

Azaline B	GnRH Receptor	Endocrinology
Azaline B is an antagonist for gonadotropin-releasing hormone (GnRH) with IC₅₀ of 1.37 nM, Azaline B can be used in research of sex hormone-related pathological states, ovulation induction and male contraception .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-149889

EGFR-IN-78	Apoptosis EGFR	Cancer
EGFR-IN-78 (compound A5)，a 2-aminopyrimidine derivative，is a reversible inhibitor of EGFR ^C797S-TK，and also an inducer of apoptosis. EGFR-IN-78 shows anti-proliferative activity，inhibits EGFR phosphorylation and arrests cell cycle at G2/M phase .

HY-P11243

EphA4 agonist compound 23	Ephrin Receptor	Neurological Disease
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .

HY-P2434

AP102	Somatostatin Receptor	Neurological Disease Metabolic Disease Cancer
AP102 is a dual *SSTR2/SSTR5*-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to *SSTR2* and SSTR5 (IC₅₀: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor *SSTR2* with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of *SSTR2* and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors ^[2].

HY-105168

TAK 044	Endothelin Receptor	Cardiovascular Disease
TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .

HY-145861

LSD1-IN-14	Histone Demethylase Apoptosis	Cancer
LSD1-IN-14 is a potent and selective LSD1 inhibitor (IC₅₀=0.89 μM). LSD1-IN-14 can significantly inhibit the proliferation of A549 and THP-1 cells and induce the apoptosis of tumor cells .

HY-162529

CDK4/6-IN-19	CDK	Cancer
CDK4/6-IN-19 (Compound II-7) is a CDK4/CDK6 inhibitor with IC₅₀ values of 0.2, 5.0 nM, respectively. CDK4/6-IN-19 also inhibits cell proliferation and can be used in cancer research .

HY-P2075

EMD 55068	Renin	Endocrinology
EMD 55068 is a renin antagonist. EMD 55068 inhibits the uptake of taurocholate .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-123599

IACS-4619	DNA/RNA Synthesis	Cancer
IACS-4619 (compound 4) is a highly selective 2-aminopyrimidine-based MTH1 (MutT homolog 1) inhibitor (IC₅₀=0.2 nM). IACS-4619 inhibits MTH1 by blocking its hydrolysis of oxidized purine nucleotides such as 8-oxo-dGTP, thereby preventing MTH1 from inhibiting the incorporation of oxidized nucleotides into DNA. IACS-4619 significantly inhibits endogenous MTH1 activity in MTH1-overexpressing U2OS cells, but without antiproliferative or cytotoxic effects on various human cancer and normal cell lines. IACS-4619 can be used in oncology research related to the MTH1 target .

HY-179683

MRP1-IN-2	P-glycoprotein	Cancer
MRP1-IN-2 (Compound 21) is a selective MRP1 inhibitor with a relatively weak inhibitory effect on P-gp. MRP1-IN-2 exhibits a strong accumulation effect of calcein, with its EC₅₀ value being 177 nM. MRP1-IN-2 enhances the activity of Doxorubicin (HY-15142A) on drug-resistant cells. MRP1-IN-2 can be used for the study of multidrug-resistant cancers .

HY-P11488

JR11-PEG3-DOTA-PSMA-03	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA	Cancer
JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC₅₀ s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ ⁶⁸Ga]. [ ⁶⁸Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .

HY-P11485

JR11-PEG3-HBED-CC-PSMA-03	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA	Cancer
JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC₅₀ s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [ ⁶⁸Ga]. [ ⁶⁸Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .

Cat. No.	Product Name	Type